BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

After securing Ernest Poku’s transfer, Bayer Leverkusen are continuously looking to strengthen their squad for the 2025/26 ...

After 23 goals and 24 assists in 142 appearances across all competitions for Bayer Leverkusen during a four year spell, Amine ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...

Crop science giant Bayer says it has settled 17,000 glyphosate cases so far and hopes for a supreme court ruling next year.

An announcement from Board of Education President Steven Blair on Friday said Mike Dominguez resigned July 31 to "pursue ...